Biocon

11 Oct 2026 · 00:13

Mazumdar-Shaw flags pharma's risk aversion

New Delhi: Indian pharmaceutical industry's aversion to taking risks poses a major hurdle for innovation and that needs to change with the use of technology, according to Biocon chairperson Kiran Mazumdar-Shaw."In pharma and biopharma, the pipeline is the lifeline," Mazumdar-Shaw said at a meeting on quality management in New Delhi last week, stressing the need to replenish the drug development pipeline continuously.Drug discovery is fraught with risks, with only one or two out of 10 candidates advancing to the final stages and meeting commercial milestones.134860305Mazumdar-Shaw was part of a

15 Oct 2026 · 00:24

Biocon clears path for cancer drug launch

Biocon on Wednesday said it has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab). The patent settlement agreement resolves all pending disputes between the two companies across multiple jurisdictions, including the US and Canada, the biopharmaceutical company said in a regulatory filing on WednesdayUnder the terms of the agreement, Biocon is cleared to launch Pebrilzo in the European Union and UK in the first quarter of calendar year (CY) 2027, followed by a launch in US in Q3 of